Abstract: The disclosed examples provide an easy and low-loss solution to reduce voltage stress on motor and cable in inverter-fed motor systems by suppressing resonances on the motor cable with apparatus coupled between the inverter output and the motor cable. Disclosed examples include various methods to mitigate voltage stress on both motor and cable, including an output filter circuit with a cable side parallel RL circuit between an inverter output and a motor cable, and an inverter to provide an inverter output signal to the output filter circuit to drive a load through the motor cable, where the cable side parallel RL circuit includes a resistor coupled in series between the inverter output and the motor cable, and an inductor connected in parallel with the resistor.

Abstract: The disclosed examples provide an easy and low-loss solution to reduce voltage stress on motor and cable in inverter-fed motor systems by suppressing resonances on the motor cable with apparatus coupled between the inverter output and the motor cable. Disclosed examples include various methods to mitigate voltage stress on both motor and cable, including an output filter circuit with a cable side parallel RL circuit between an inverter output and a motor cable, and an inverter to provide an inverter output signal to the output filter circuit to drive a load through the motor cable, where the cable side parallel RL circuit includes a resistor coupled in series between the inverter output and the motor cable, and an inductor connected in parallel with the resistor.

Abstract: The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.

Abstract: The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.

Abstract: The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.

Abstract: The invention provides methods for increasing the level of human fetal hemoglobin in a subject or cell in need thereof. The methods can be used with subjects suffering from a ?-chain hemoglobinopathy including thalassemia (e.g., ?-thalassemia) or sickle cell anemia.

Abstract: The invention provides methods for increasing the level of human fetal hemoglobin in a subject or cell in need thereof. The methods can be used with subjects suffering from a ?-chain hemoglobinopathy including thalassemia (e.g., ?-thalassemia) or sickle cell anemia.

Abstract: The invention provides methods and materials for screening for polymorphic variants in ABCB1 and diagnosing altered susceptibilities for drug-induced heart rhythm irregularities based on the same. These methods allow better treatment regimens for using drugs that bind a protein encoded by the ABCB1 and/or induce heart rhythm irregularities such as the anti-cancer drug FK228.

Abstract: Disclosed are topical compositions comprising at least one histone deacetylase (HDAC) inhibitor (HDI) and a carrier comprising petrolatum. Methods for using such compositions to treat or inhibit cancer and various skin diseases are also disclosed.

Abstract: The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.